Celaid Therapeutics secures Series B funding from Shionogi and Teikoku
Biotechnology company Celaid Therapeutics completed its Series B financing round with backing from Shionogi and Teikoku Ventures to prepare US clinical trials for candidate CLD 001
Celaid Therapeutics Inc., based in Tokyo, Japan, has successfully raised JPY 400 million (approximately USD 2.6 million) through its Series B financing round. Two prominent investors, Shionogi & Co., Ltd. and Teikoku Ventures, Inc., joined the company's existing backers. This investment brings Celaid's total funding raised to approximately JPY 3.42 billion (around USD 22.1 million) to date.
The new funding round will be primarily used for manufacturing, safety assessment, clinical development, and regulatory activities in support of Celaid's lead product, CLD-001. CLD-001 is a novel ex vivo-expanded hematopoietic stem cell therapy targeted at severe pediatric non-malignant diseases. The company is on track to initiate a first-in-human clinical trial in the United States.
The investment from Shionogi & Co. and Teikoku Ventures is seen as a significant endorsement of Celaid's hematopoietic stem cell expansion technology. The company's CEO, Nobuyuki Arakawa, expressed gratitude for the support and shared the company's ambition to become a global leader in the hematopoietic stem cell field.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
